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and Immunology, Medical University of Vienna, Vienna, AustriaIgE-associated food allergy affects approximately 3% of the
population and has severe effects on the daily life of
patients—manifestations occur not only in the gastroin-
testinal tract but also affect other organ systems. Birth
cohort studies have shown that allergic sensitization to
food allergens develops early in childhood. Mechanisms of
pathogenesis include cross-linking of mast cell– and
basophil-bound IgE and immediate release of inﬂamma-
tory mediators, as well as late-phase and chronic allergic
inﬂammation, resulting from T-cell, basophil, and eosino-
phil activation. Researchers have begun to characterize the
molecular features of food allergens and have developed
chip-based assays for multiple allergens. These have pro-
vided information about cross-reactivity among different
sources of food allergens, identiﬁed disease-causing food
allergens, and helped us to estimate the severity and types
of allergic reactions in patients. Importantly, learning
about the structure of disease-causing food allergens has
allowed researchers to engineer synthetic and recombi-
nant vaccines.Keywords: IgE-Associated Food Allergy; Allergen; IgE;
Diagnosis; Multiallergen Test; Therapy; Immunotherapy.
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Open access under CC BY license.Tdevelop adverse reactions to foods also termed
food intolerance.1 These reactions can be considered toxic
or nontoxic (Figure 1).2 Among the nontoxic reactions,
those that are not immune-mediated, such as those
involving enzyme defects (eg, vasoactive amines) or re-
actions to certain substances (eg lactose intolerance), are
far more common than immune-mediated reactions.2
Nevertheless, immune-mediated reactions affect millions
of people, are responsible for signiﬁcant morbidity and
health care costs, and can cause severe life-threatening
reactions that lead to death.3–5 Food allergy was deﬁned
by an expert panel of the National Institute of Allergy and
Infectious Diseases as “an adverse health effect arising
from a speciﬁc immune response that occurs reproducibly
on exposure to a given food.” This response comprises
basically all types of immune-mediated reactions,including those caused by the adaptive and innate immune
system (Figure 1).6
The term allergy was coined in 1906 by the Austrian
pediatrician Clemens von Pirquet,7 who described cases of
serum sickness in children treated with antibody prepara-
tions. According to Coombs and Gell,8 there are 4 major
types of allergic reactions based on pathogenesis mecha-
nisms. The most common forms of immune-mediated
adverse reactions to foods (type I reactions) always are
characterized by the development of IgE against food al-
lergens. It can be accompanied by inﬂammation, induced by
cellular components, and mediated by T cells and eosino-
phils. Patients with IgE-associated food allergy can be
identiﬁed based on the detection of food allergen–speciﬁc
IgE in serum and body ﬂuids, and by measuring IgE-
mediated cellular and in vivo responses.4
Although it is tempting to speculate that food anti-
gen–speciﬁc IgG can cause adverse reactions via type II or
type III hypersensitivity, there is no solid experimental
evidence to support the relevance of these reactions to food
allergies that develop in patients (Figure 1). Accordingly,
several position papers strongly recommend against testing
for food antigen–speciﬁc IgG in the diagnosis of food
allergy.9,10
Type IV hypersensitivity, which mainly involves food
antigen–speciﬁc T-cell responses and can damage the gut
mucosa, is associated with disorders such as celiac disease.
Celiac disease is characterized by a hypersensitivity reaction
against the wheat gluten fraction comprising alcohol soluble
gliadins and acid-, alkali-soluble glutenins, accompanied by
an autoimmune component.11 Type IV hypersensitivity re-
actions also might be involved in food protein–induced
enterocolitis (Figure 1).12 Studies have shown that certain
food proteins can induce inﬂammation via direct activation
Figure 1. Classiﬁcation of food intolerance. Adverse
reactions to food can be classiﬁed as toxic or nontoxic
reactions. Nontoxic reactions are categorized further as
immune-mediated or non–immune-mediated. The most
common adverse reactions are based on non–immune-
mediated mechanisms such as enzyme defects as observed
in lactose intolerance. Hypersensitivities involving the adap-
tive immune system can be subdivided into 4 categories
(types I–IV). Type I reactions are always associated with the
formation of IgE against food allergens and therefore can be
called IgE-associated food allergies. There is ﬁrm evidence
for an involvement of IgG in type II or type III reactions in
immune-mediated adverse reactions to food, whereas type IV
reactions, which involve T cells, have important roles in dis-
orders such as celiac disease. There is evidence that the
innate immune system, which includes complement, Toll-like
receptors, and innate immune cells, also mediates immune
reactions against certain food components.
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trypsin inhibitors and certain milk oligosaccharides can
cause intestinal inﬂammation via activation of Toll-like re-
ceptor 4,13,14 and certain allergens have been shown to
stimulate the innate immune system.15 Innate immune
mechanisms might mediate nonceliac gluten sensitivity.16
In developed countries, IgE-associated food allergy
affects 3%–8% of children and 1%–3% of adults.3–5 It not
only is common, but often is a serious and life-threatening
health condition that requires accurate diagnosis and has
strong effects on an individual’s dietary habits and social
life. Milk, eggs, wheat, peanuts, nuts, sesame, ﬁsh, fruits, and
vegetables are common inducers of IgE-associated food al-
lergy.4 Allergies to foods such as milk, egg, and wheat often
are outgrown (patients acquire tolerance), whereas allergies
to peanuts, tree nuts, and ﬁsh allergies often persists over a
lifetime.3 The exact incidence of food allergies has not been
fully established because there are discrepancies among
ﬁndings from studies in which food allergies were self-
reported vs those diagnosed by various assays (eg, provo-
cation, skin test, or serologic tests).4,17
The prevalence and severity of food allergies seem to be
increasing. In addition to genetic factors, a number ofenvironmental, cultural, and behavioral factors affect the
frequency, severity, and type of allergic manifestations in
patients.18–21 A recent study identiﬁed epigenetic differ-
ences in CD4þ T cells from children with IgE-mediated food
allergies, compared with children without food aller-
gies—differences such as these might contribute to the
development of a food allergy.22 According to the hygiene
hypothesis, decreases in family size and improvements in
personal hygiene have contributed to the increased preva-
lence of IgE-mediated allergies. On the other hand, factors
such as an anthroposophic lifestyle (eating organic foods
that contain lactobacilli and restrictive use of antibiotics,
antipyretics, and vaccines) have been associated with a
reduced incidence of allergies.23,24 It has been proposed that
insufﬁcient exposure to dietary and bacterial metabolites
might have contributed to increases in inﬂammatory dis-
orders in Western countries.25
Allergic Sensitization and Secondary
Immune Responses
The term allergic sensitization describes the ﬁrst induc-
tion of an allergic immune response upon allergen
encounter.26,27 Two routes of allergic sensitization are well
established (Figure 2A). Class 1 food allergens (eg, milk, egg,
or peanut) are oral allergens that cause sensitization via the
gastrointestinal tract.28 Class 2 food allergens are aero-
allergens (eg, major birch pollen allergen Bet v 1) that cause
sensitization via the respiratory tract. Immune responses
against these allergens can cross-react with homologous
food allergens (eg, major apple allergen Mal d 1) to cause
symptoms.29–31
It recently was proposed that people become sensitized
to food allergens via skin contact, but there have been few
studies of this process.18 Interestingly, studies of animal
models have indicated that epicutaneous sensitization leads
to expansion of IgE-dependent intestinal mast cells and
food-induced allergic reactions.32,33 For an overview of food
allergen sources that may cause sensitization via the res-
piratory tract and skin, see the article by Asero and
Antonicelli.34
Determinants of allergic sensitization include features of
the epithelial barrier, the allergen itself (whether allergens
are stable and not degraded in the environment or gastro-
intestinal tract), nonallergenic components of the food ma-
trix, and substances that act as adjuvants (Figure 2A).35 For
example, food allergens have been proposed to have greater
stability during digestion than other molecules in food.36
Intrinsic factors (eg, genetic factors such as mutations in
the ﬁlaggrin gene) and exogenous factors (eg, alcohol, anti-
inﬂammatory drugs, pathogens, or stress) have been pro-
posed to reduce the barrier function of the intestinal
epithelium and facilitate sensitization.37–39 On the other
hand, secretory antibodies, particularly secretory IgA (SIgA),
have important roles in reinforcing the epithelial barrier.
Mice deﬁcient in SIgA and secretory IgM are prone to
develop food allergen–induced anaphylactic shock, which
can be overcome by induction of tolerance with T-regula-
tory cells.40,41
Figure 2. Time course, pathogenesis, and manifestations of food allergies. IgE-associated food allergies appear to develop
early in childhood. This process is termed allergic sensitization. (A) Allergen contact via the gastrointestinal tract, via the
respiratory tract, and eventually via the skin induces IgE production (primary sensitization) in genetically predisposed in-
dividuals. Repeated allergen contact activates allergen-speciﬁc T cells and induces IgE responses during the secondary
immune response. Factors that affect the epithelial barrier (red arrows) and the extent to which allergens are digested or
degraded are important for primary sensitization and boosting of secondary immune responses. SIgA and T-regulatory cells
may be important for exclusion of allergens from the intestinal lumen and induction of tolerance, respectively. (B) The balance
between allergen-speciﬁc IgE and blocking IgG helps determine whether or not a patient will develop symptoms. Allergen
avoidance could reduce levels of allergen-speciﬁc IgE to below the threshold for symptom induction (lower panel), whereas
exposure could increase production of IgE, leading to symptoms (upper panel). If allergen exposure induces allergen-speciﬁc
IgG, which blocks the interaction between the allergen and IgE, then symptoms might be reduced (middle panel). (C) Allergy
symptoms are caused by repeated contact with the oral allergen, via the immediate allergic reaction (allergen-induced cross-
linking of mast cell–bound IgE by allergen and then activation of allergen-speciﬁc T cells), and then by other inﬂammatory cells,
such as eosinophils and basophils, during late-phase and chronic inﬂammation. Factors that affect the epithelial barrier and
the extent of allergen degradation affect the amount of allergen intrusion and the magnitude and type of inﬂammation. After
allergen ingestion, inﬂammation develops not only in the intestine, but in other organs, such as the skin, respiratory tract, and
circulatory system (right). These allergens and allergen fragments are internalized and distributed throughout the body (left).
MHC, major histocompatibility complex; T-reg, T-regulatory cell; TCR, T-cell receptor.
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the atopic predisposition of individuals. These determine
their susceptibility to develop allergic immune responses
against allergens.42 In atopic individuals who have a pre-
disposition toward developing IgE-associated allergies,
encounters with allergen activate, after processing by
antigen-presenting cells (eg, dendritic cells or B cells),
allergen-speciﬁc T-helper 2 (Th2) cells, which produce cy-
tokines such as interleukin (IL)4 and IL13. These cytokines
induce class switching and production of allergen-speciﬁc
IgE.43–45 Primary allergic sensitization (such as a classswitch toward IgE production) occurs early in life and
leads to T-cell and IgE memory, which can be boosted
with repeated allergen contact (secondary immune
response).46–49 Upon contact with a primary food allergen,
nonallergic individuals produce allergen-speciﬁc IgG and
IgA, which do not induce allergic reactions. The formation of
food allergen–speciﬁc IgE is a main feature of IgE-associated
food allergy and its diagnosis.
Analyses of the time courses of allergic sensitization to
respiratory and food allergen sources in large birth cohort
studies have shown that food allergies and their associated
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life, there is a reverse trend—food allergies often are
outgrown and respiratory allergies increase and domi-
nate.50 Interestingly, the prevalence of food allergies is
approximately 10-fold lower than that of respiratory al-
lergies.4,51 This could be because oral exposure to allergens
activates tolerance mechanisms (via regulatory T cells) and
less frequently results in allergic sensitization than respi-
ratory exposure to allergens.52,53
Several cellular mechanisms seem to inﬂuence primary
allergic sensitization vs tolerance in the intestine. Tolerance
can be mediated by antigen presentation by dendritic cells,
which interact with C-type lectin receptors54; dendritic
cell–bound IgE can down-regulate allergic inﬂammation at
mucosal sites.55 Children with an egg allergy were reported
to have reduced function of neonatal T-regulatory cells
compared with children without an egg allergy.56 On the
other hand, children who outgrew a cow’s milk allergy had
increased T-regulatory cell responses.57 These ﬁndings
indicate that T-regulatory cells modulate the development
of food allergies.58
After primary sensitization, the allergic immune
response is boosted with repeated exposure to allergen,
increasing activation of allergen-speciﬁc T cells and pro-
duction of IgE.
In persons with a respiratory allergy, the IgE response is
boosted by contact with a mucosal allergen48 and, inter-
estingly, does not seem to require T-cell help.59–61 Another
interesting feature of the established secondary IgE
response is that in adults with an allergy, the proﬁle of al-
lergens recognized by IgE does not change substantially,
whereas it seems that young children can be sensitized to
new allergens.62,63 In the case of a respiratory allergy,
allergen contact through the respiratory mucosa strongly
boosts IgE production, but has little inﬂuence on the other
classes of allergen-speciﬁc antibodies (eg, IgA or IgG).48 The
responding B ε memory cells may reside in the respiratory
mucosa or the adjacent lymphoid tissues,64 but little is
known about the precise location of the cells involved in
secondary IgE responses in allergic patients.65
The mechanisms by which food allergen–speciﬁc IgE
responses are boosted in patients with food allergies are
poorly understood. When food allergens were administered
orally, patients had strong increases in the production of
allergen-speciﬁc IgG, accompanied by an initial boost of
IgE.66–68 These ﬁndings indicated that allergen ingestion can
boost allergen-speciﬁc production of IgG as well as IgE. It is
possible that oral allergens can boost production of disease-
causing IgE, as well as that of potentially protective IgG; this
might explain why elimination or continued intake of food
allergens can beneﬁt patients.69,70
It is clear that avoidance of food allergens over a pro-
longed period of time reduces levels of allergen-speciﬁc IgE
below the threshold level for symptoms (Figure 2B). How-
ever, there is controversy about whether intake of food al-
lergens is beneﬁcial. If food allergen intake mainly
stimulates production of protective IgG antibodies, toler-
ance could be induced and allergen-speciﬁc IgE production
could be reduced. However, insufﬁcient IgG productioncould cause IgE levels to increase, leading to increased
sensitivity and symptoms (Figure 2B). Several recent
studies have shown that the induction of allergen-speciﬁc
IgG antibodies, which block IgE recognition of food aller-
gens, is associated with the successful immunotherapy for
food allergy.68
Pathogenesis and Manifestations of
Food Allergy
Upon interaction with food antigens, IgE becomes
cross-linked and binds to mast cells and basophils via the
high-afﬁnity receptor FcεRI (Figure 2C).71 This process ac-
tivates these cells, leading to the release of granules that
contain preformed inﬂammatory mediators (eg, histamine),
as well as de novo synthesis and/or release of inﬂammatory
mediators (eg, leukotrienes), proteases (eg, tryptase), in-
ﬂammatory cytokines (eg, IL4), and chemotactic molecules.
Mast cells and basophils are activated within a few minutes
of IgE cross-linking, therefore this process it called an
immediate allergic reaction; symptoms occur shortly after
allergen contact.
Because food allergens enter the blood via the gastro-
intestinal tract, symptoms can develop directly at the sites
of allergen contact (eg, mouth, esophagus, and/or intestine),
or in other organs. Systemic reactions occur when allergens
capable of cross-linking effector cell-bound IgE pass the
barrier of the mucosa into the circulation (Figure 2C, right).
Allergen uptake also may affect the circulatory and nervous
systems.
Factors that contribute to the type and severity of re-
actions include the amount of ingested allergen, the stability
of the allergen against digestion, and the permeability of the
epithelial barrier (Figure 2C). The immediate allergic reac-
tion leads to intense inﬂammation that can become life-
threatening. The release of vasoactive mediators into the
circulation can lead to vascular collapse and anaphylactic
shock.72 Supplementary Table 1 summarizes the clinical
manifestations of food allergies, the organ systems affected
by IgE-mediated mast cell and basophil degranulation, and
the clinical aspects of gastrointestinal food allergy.3,6
Studies performed with well-deﬁned reagents (eg,
monoclonal IgE, in vitro cellular systems, deﬁned aller-
gens, and IgE epitopes) have shown that the degranulation
of effector cells, and therefore the intensity of the
immediate-type reaction, increases with the number of IgE
epitopes on an allergen, high levels of allergen-speciﬁc IgE,
and high-afﬁnity allergen-speciﬁc IgE.73–75 The fact that
high levels of allergen-speciﬁc IgE cause up-regulation of
FcεRI on mast cells and basophils, and thereby a more
dense loading of these cells with IgE, could account for the
association between levels of allergen-speciﬁc IgE against
stable food allergens and the severity of allergic reac-
tions.76–78 In addition to the levels of FcεRI on mast cells,
the number of intestinal mast cells and basophils and
(probably related to mast cell numbers and activation) the
levels of intestinal tryptase also seem to be related to the
severity of reactions to food allergens.79–81 Interestingly,
studies performed in animal models have shown that
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mast cells.82
In addition to the immediate allergic reaction (the most
frequent pathogenic mechanism of IgE-associated allergies),
late-phase allergic reactions also occur after allergen con-
tact; there are 2 types. The late-phase response to allergens
has been studied in mainly cutaneous models, such as skin
blister and skin chamber models. Several hours after
allergen contact and the immediate reaction, there is an
inﬂux of basophils and eosinophils.83 This inﬂux is steroid-
sensitive and seems to involve granulocyte-macrophage
colony-stimulating factor.84 Relatively little is known
about the importance of late-phase reactions in food allergy,
but it is tempting to speculate that they could be involved in
food allergen–induced forms of eosinophilic gastroenter-
itis.85 In fact, data from experimental animal models have
indicated that thymic stromal lymphopoetin–induced baso-
phil responses promote eosinophilic esophagitis.86 Inter-
estingly, it also has been shown that enteric eosinophils not
only contribute to inﬂammation, but control dendritic cells
to initiate primary Th2 cell–mediated immune responses,
indicating a complex interaction among cells in food
allergies.87
In addition to the late-phase responses, delayed-type
reactions can occur 24–48 hours after allergen contact.
These resemble features of a type IV hypersensitivity reac-
tion, involving allergen-speciﬁc T cells. Allergen-speciﬁc T
cells can be activated via IgE-dependent and IgE-
independent pathways (Figure 2). In fact, in patients with
allergies, antigen-presenting cells express FcεRI as well as
the low-afﬁnity receptor for IgE (FcεRII also known as
CD23). The cells use this receptor for IgE-facilitated allergen
presentation—a process found to be more effective for T-
cell activation than allergen presentation without IgE.88,89
Studies performed with allergen peptides that do not react
with IgE and recombinant allergen derivatives showed that
activation of allergen-speciﬁc T cells also can occur without
IgE, and lead to delayed-type allergic reactions in
patients.90,91
Induction of atopic dermatitis by food allergens has been
shown to require not only Th2 cells (and Th2 cytokines such
as IL4, IL13, and IL5—a cytokine that activates eosinophils),
but also Th1 cells, which mediated delayed allergic inﬂam-
mation.92 Interferon-g, secreted by allergen-speciﬁc Th1
cells, was shown to induce epithelial damage in a model of
respiratory allergy.93
The immediate- and delayed-type allergic inﬂammation
that occurs during IgE-associated food allergy has been
studied extensively in patients with oral allergy syndrome
(OAS) (Supplementary Table 1). OAS is caused by sensiti-
zation to respiratory allergens that structurally are similar
to allergens in foods, leading to a cross-reactive immune
response. The most common form of OAS develops with
sensitization to the major birch pollen allergen, Bet v 1. In
patients with this form of OAS, the immune response cross-
reacts with allergens in plant-derived food such as apples,
nuts, carrots, and celery.94 This leads to local allergy
symptoms of the immediate type (local itching and swelling
of the lips or tongue), caused by IgE-mediated mast celldegranulation.95 However, Bet v 1–related plant food aller-
gens are digested by the gastrointestinal tract, therefore
systemic reactions occur only in exceptional cases (such as
after consumption of large amounts of the plant food
allergens during exercise), and anaphylactic shock does not
occur.96 Likewise, cooking destroys IgEs, but leaves pep-
tides recognized by allergen-speciﬁc T cells intact.97 Inges-
tion of Bet v 1–related plant food allergens therefore can
activate allergen-speciﬁc T cells by IgE-independent mech-
anisms, and induce late-phase and chronic allergic inﬂam-
mation to cause disorders such as atopic dermatitis in
sensitized patients.98
Information on the time until onset of allergic reactions
after food allergen intake (minutes–hours vs hours–days)
and allergy phenotype (eg, urticaria vs atopic dermatitis)
can help to determine whether the symptoms involve im-
mediate IgE-mediated mast cell or basophil activation, or
late-phase or chronic allergic inﬂammation caused by T-cell
or eosinophil activation. Then, it is possible to select the
most appropriate therapy. For example, immediate re-
actions would be treated with antihistamines, anti-
leukotrienes, epinephrine, mast cell stabilizers, or anti-IgE,
whereas late-phase chronic inﬂammation would be treated
with steroids or anti-IL5.Preventing Food Allergies
According to the current food allergy and anaphylaxis
guidelines of the European Academy of Allergy and Clinical
Immunology,99 there are no restrictions regarding diet for
mothers during pregnancy and lactation. Exclusive breast-
feeding is recommended for the ﬁrst 4–6 months of life,
which prevents the development of allergies. If breastfeed-
ing is not possible, hypoallergenic formulas with docu-
mented preventive effects are recommended for high-risk
children. Breastfeeding transfers protective SIgA to the
child, which may prevent allergic sensitization, and avoids
early exposure to potential food allergens. This process may
involve the uptake of SIgA-allergen complexes via receptors
on M cells. Although certain studies have shown that early
feeding of probiotics can reduce the development of allergic
manifestations, particularly eczema, other studies have
found that probiotic supplementation during early child-
hood did not prevent the development of allergic dis-
eases.100,101 Likewise, there is no clear evidence that the
administration of prebiotics or lipopolysaccharides can
prevent the development of allergies.102 Accordingly, there
is currently no evidence to support the use of prebiotics or
probiotics in the prevention of food allergies. However,
research is underway to identify speciﬁc probiotics or pre-
biotics that affect allergy development.99Diagnosis and Management
Once a patient is diagnosed with a food allergy, it be-
comes important to identify the allergen(s) that cause the
disorder and determine if it is mediated by IgE. If so,
treatments for IgE-associated allergies can be selected
(Figure 3). In early studies of food allergies,103 diagnoses
Figure 3. Diagnosis and
management of IgE-
associated food allergies.
The diagnosis of a food
allergy involves a case
history and a demonstra-
tion of allergen-speciﬁc
IgE production. Provoca-
tion tests and diets are
used to identify disease-
causing allergens. Based
on this information,
allergen-speciﬁc forms of
treatment can be selected.
This approach currently
is being introduced into
clinical practice. CFSE,
carboxyﬂuorescein succi-
nimidyl ester; ELISA,
enzyme-linked immuno-
sorbent assay; RBL, rat
basophilic leukemia.
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to document symptoms and offending foods.6 For more in-
formation on the diagnosis of food allergies, see Figure 3
and articles by Sicherer and Sampson,3 De Silva et al,5 and
Boyce et al.6
Results from serologic and in vitro tests alone are not
sufﬁcient for the diagnosis of IgE-associated food allergies
because the presence of allergen-speciﬁc IgE is not always
associated with symptoms.104 This might be because certain
antigens in food react with IgE but do not have allergenic
activity. Furthermore, certain allergens easily are degraded
and/or do not pass the epithelial barrier in sufﬁcient
quantities. For this reason, provocation tests often are
useful and required to conﬁrm IgE-associated food allergy.
Skin tests are relatively easy to perform, but just as for IgE
tests, results are not always associated with symptoms. Skin
tests can detect IgE-mediated mast cell degranulation; these
include the skin-prick test, prick-to-prick test, and intra-
dermal test. Atopy patch tests can detect delayed-type re-
actions mediated by T-cell reactions.
Oral provocation tests are the most accurate in the
diagnosis of clinically relevant IgE-associated food allergies
once allergen-speciﬁc IgE has been detected. These involve
placing patients on elimination diets, and re-introducing
foods or providing an open oral challenge. A double-blind,
placebo-controlled food challenge is the standard forantigen identiﬁcation.105 However, the double-blind, pla-
cebo-controlled food challenge can induce severe reactions
and requires careful planning and well-equipped clinical
facilities.
Several provocation tests involve the application of
mucosal allergens.106 Major advances in the diagnosis of
food allergies and identiﬁcation of disease-causing allergens
include new in vitro multiplex allergy tests, which involve
puriﬁed allergens.
IgE-associated food allergies are managed with allergen-
speciﬁc treatments such as avoidance of the disease-causing
allergens via diets that ensure balanced nutrition with the
least possible effects on quality of life. The elimination diet
is the most important and relevant long-term management
strategy for food allergies.5 Once the offending food aller-
gens have been identiﬁed the allergenic food must be
avoided. For a summary of the management paths and
guidelines for treatment, see the articles by Sicherer and
Sampson,3 De Silva et al,5 and Boyce et al.6 For patients with
a cow’s milk allergy, milk can be replaced with extensively
hydrolyzed milk formulas.107
Allergen-speciﬁc immunotherapy (SIT) is currently the
only allergen-speciﬁc and disease-modifying treatment that
has long-term effects.108 SIT is used mainly to treat respi-
ratory allergies, and less frequently to treat food allergies
because standardized vaccines are not available. In the case
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istration of the offending food instead of a vaccine.68,109
Progress in the molecular characterization of food aller-
gens will lead to the development of deﬁned vaccines for the
treatment of food allergies, as for respiratory allergens,
which may become available in the future.110–112
Patients diagnosed with IgE-mediated food allergies can
be given medications to reduce their symptoms.4,5 These
can be selected based on the involvement of IgE-mediated
mast cell or basophil degranulation (antihistamines, anti-
leukotrienes, epinephrine, anti-IgE), or T cells or eosinophil
activation (steroids, anti-IL5) (Figure 3).3,6 This procedure
is beginning to enter clinical practice.
Food Allergen Structure, Pathogenesis,
and Diagnosis
Since the 1980s, we have learned much about the
structure and immunologic characteristics of allergens, andFigure 4. Component-resolved diagnosis of a food allergy. D
molecules (components); these can be produced as recombina
can be classiﬁed into IgE-reactive components (green), which a
little or no clinical reactions; components that induce mild or m
associated with severe and systemic allergic reactions (red). Mic
of patients. This process can be used to identify individual allerg
likely to respond. The severity of reactions also can be predictethe clinical reactions they can cause.110 Researchers have
produced recombinant allergens comprising repertoires of
the most common antigens. Instead of ill-deﬁned allergen
extracts, which are prepared from the allergen sources (eg,
wheat, apple, milk, or peanuts) (Figure 4) and consist of
mixtures of various allergens and nonallergenic materials,
pure allergen molecules are available for diagnosis and
allergen-speciﬁc therapy. Puriﬁed recombinant allergens
can be used to determine a patient’s IgE reactivity proﬁle.
Many allergen sources contain antigens that have little
or no clinical relevance because they are poor inducers of
allergic reactions. These include IgE-reactive carbohydrate
epitopes without allergenic activity,113 or molecules that
induce only mild or local symptoms. Other molecules can
induce severe systemic allergic reactions (Figure 4).
Marker allergens have been identiﬁed from the most
common food allergen sources (eg, apple, peanut, milk, and
wheat).114–118 Marker allergens are those found only in
speciﬁc sources, and can be used to conﬁrm sensitizations toifferent sources of food allergens contain several allergenic
nt proteins or puriﬁed from natural sources. These allergens
re poor activators of inﬂammatory cells and therefore induce
ainly local symptoms (yellow); and components that often are
roarray technology can be used to determine reactivity proﬁles
ens that cause disease and foods to which patients are most
d.
Figure 5. Allergen-speciﬁc forms of prophylaxis and treatment. Multiplex allergen systems can be used to identify disease-
relevant food allergens in populations. (A) Based on the mapping of antigen epitopes recognized by patients’ IgE and T
cells, 4 molecular approaches are being developed for prophylaxis and treatment. These are as follows: recombinant wild-type
allergens, carrier-bound B-cell epitope–containing peptides (which do not react with IgE, have reduced allergen-speciﬁc
epitopes recognized by T cells, and induce allergen-speciﬁc IgG), recombinant hypoallergens (which have reduced reac-
tivity with IgE and fewer epitopes that interact with T cells, and induce allergen-speciﬁc IgG), and peptide epitopes that interact
with T cells (but do not react with IgE or induce allergen-speciﬁc IgG). (B) Allergen-speciﬁc treatment can be prophylactic
(prenatal or early postnatal) or be given after sensitization has taken place (speciﬁc immunotherapy). Active vaccination,
passive immunization with allergen-speciﬁc antibodies, and tolerance induction are options.
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sources. Patients who are sensitized to these can develop
symptoms after ingestion of seemingly unrelated foods.
Individual allergen molecules are named and listed by the
nomenclature committee of the World Health Organization
and International Union of Immunological Societies.119 For
an overview of the general biochemical characterization and
features of allergens (see the article by Valenta120). Several
databases also store information on allergens, including
names, classiﬁcations, and characteristics (eg, http://
www.allergen.org/; http://farrp.unl.edu/resources/farrp-
databases; http://allergen.nihs.go.jp/ADFS/; http://www.
allergome.org/; http://www.meduniwien.ac.at/allergens/
allfam/; and http://www.allergenonline.org/).Table 1 shows some important plant food and animal
food allergen families. According to a recent classiﬁcation,
allergens from different sources can be grouped into fam-
ilies with similar biologic functions, primary structure,
and immunologic cross-reactivity.121 A few examples for
allergens from different sources that can be attributed to
these structurally related allergen families are shown in
Table 1.
The diagnosis of food and other allergies has transi-
tioned from the identiﬁcation of allergen sources without
knowledge of the molecules that cause the symptoms, to the
precise identiﬁcation of allergy-inducing molecules. These
processes are called “component-resolved allergy diagnosis”
and “molecular allergy diagnosis.”122
Table 1.Plant Food and Animal Food Allergen Families.
Family Function Selected allergens (names/sources)
Plant food allergen families
Prolamins Seed storage proteins Sec c 20/Rye; Tri a 19/wheat; Tri a 36/wheat
Nonspeciﬁc lipid transfer
proteins
Involved in lipid transport, plant defense Act d 10/Kiwi; Api g 2/celery; Ara h 9/peanut;
Cas s 8/chestnut; Cor a 8/hazelnut; Jug r 3/walnut;
Lyc e 3/tomato; Mus a 3/banana; Pru du 3/almond;
Pru p 3 /peach; Tri a 14/wheat; Zea m 14/maize
2S albumins Seed storage proteins Ana o 3/cashew nut; Ara h 2/peanut; Ber e 1/Brazil
nut; Fag e 2/buckwheat; Gly m 8/soybean;
Jug r 1/walnut; Ses i 1/sesame; Sin a 1/mustard
Bet v 1 family Pathogenesis-related proteins Api g 1/celery; Ara h 8/peanut; Cor a 1/hazelnut;
Dau c 1/carrot; Gly m 4/soybean; Mal d 1/apple;
Pru p 1/peach
Cupin superfamily
7S (vicilin-like) globulins Seed storage proteins Ana o 1/cashew nut; Ara h 1/peanut;
Gly m 5/soybean; Jug r 2/walnut; Pis v 3/pistachio
11S (legumin-like) globulins Seed storage proteins Ana o 2/cashew nut; Ara h 3/peanut; Ber e 2/Brazil
nut; Cor a 9/hazelnut; Gly m 6/soybean;
Jug r 4/walnut; Pru du 6/almond
Cysteine protease C1 family Cysteine proteases Act d 1/kiwi; Gly m Bd 30K/soybean
Proﬁlins Actin-binding proteins Act d 9/kiwi; Api g 4/celery; Ara h 5/peanut;
Cuc m 2/melon; Dau c 4/carrot; Gly m 3/soybean;
Lyc e 1/tomato; Mus a 1/banana; Ory s 12/rice;
Pru av 4/cherry; Pru du 4/almond; Pru p 4/peach;
Tri a 12/wheat
Animal food allergen families
Tropomyosin family Actin-binding proteins in muscle Pen m 1/shrimp
Parvalbumin family Muscle proteins, involved in muscle contraction Cyp c 1/carp; Gad c 1/cod; Ran e 2/frog;
Sal s 1/salmon; Seb m 1/redﬁsh; Xip g 1/swordﬁsh
Caseins Mammalian milk proteins, form stable micellar
complexes
Bos d 8–Bos d 12/cow’s milk
Transferrin family Sulfur-rich ion-binding glycoproteins from milk
and hen’s egg white
Bos d Lactoferrin/cow’s milk; Gal d 3/hen’s egg
Serpins Serine protease inhibitors Gal d 2/hen’s egg
Arginine kinases Adenosine triphosphate: guanido
phosphotransferases
Pen m 2/shrimp
Lipocalins Carrier proteins Bos d 5/cow’s milk
Lysozyme family Enzymatic activity, lactose synthesis in milk Bos d 4/cow’s milk; Gal d 4/hen’s egg
Ovomucoids Kazal inhibitors, contain Kazal-type inhibitor
repeats
Gal d 1/hen’s egg
Albumins Serum albumins, transport proteins Bos d 6/cow’s milk; Gal d 5/hen’s egg
NOTE. Biologic functions of the proteins and selected allergens from various food allergen sources are named according to the
International Union of Immunological Societies allergen nomenclature.
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number of well-characterized allergen molecules has
required the development of new diagnostic tests. We now
can test small volumes of serum for IgE reactivity against
multiple allergens simultaneously. Allergen chips containing
micro-arrayed allergen molecules have been developed for
this purpose123; they can be used to analyze serum samples
for reactivity with a comprehensive set of molecules. This
approach is ideal for analysis of children, or studies of dif-
ferences or changes in allergic immune responses in large
groups, such as birth cohorts.124 Based on component-
resolved allergy diagnosis, the type and severity of symp-
toms can be predicted. Furthermore, the most relevant
components can be identiﬁed to aid in the development of
allergen-speciﬁc treatments and preventative strategies.125Allergen-Speciﬁc Prevention
and Therapy
A major limitation of SIT is the difﬁculty in preparation of
effective and safe vaccines from natural allergen sources.126
However, based on the knowledge of the structure of the
disease-causing allergens, it has become possible to produce
new forms of allergy vaccines based on puriﬁed allergen
molecules (Figure 5).110 Clinical trials have shown the efﬁ-
cacy of immunotherapies that include recombinant allergens
in the wild-type, folded forms.127 Vaccines can be developed
based on these allergens, under standardized conditions.
However, wild-type allergens still contain epitopes that
activate IgE and T cells, and therefore might induce allergic
reactions in patients. Three approaches, based on modiﬁed
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Sallergens, have been developed to make allergy vaccines
more safe, effective, and convenient. These allow for selec-
tive targeting of different facets of the allergic immune
response. They include synthetic allergen-derived peptides
that contain allergen-speciﬁc T-cell epitopes without IgE
reactivity.128 Because of their small size, peptide vaccines
can induce T-cell tolerance without allergen-speciﬁc IgG
responses. Recombinant hypoallergenic allergen derivatives
are characterized by strongly reduced IgE reactivity, and
contain allergen-speciﬁc T-cell epitopes. After internaliza-
tion, they can induce allergen-speciﬁc IgG responses.129
Carrier-bound peptides that contain B-cell epitopes are
fusion proteins that consist of an allergen-unrelated carrier
protein and nonallergenic peptides from the IgE binding
sites of allergens. They lack IgE reactivity and most allergen-
speciﬁc T-cell epitopes, but can induce allergen-speciﬁc IgG
antibodies.130
These approaches are in immunotherapy trials for pa-
tients with respiratory allergies. Results from clinical
studies have indicated that the induction of allergen-speciﬁc
IgG that blocks the interaction between allergens and IgE
are necessary for immunotherapy of respiratory and food
allergies.66,108 It therefore is conceivable that food allergies
can be treated in a similar manner as respiratory aller-
gies—not only by oral SIT but also by vaccination protocols.
In fact, a vaccine for ﬁsh allergies, based on a recombinant
hypoallergenic derivative of the major ﬁsh allergen (Cyp c
1), is being evaluated in a phase 2 immunotherapy trial in a
European Union–funded research program.112,131–133
Food allergies also might be prevented with prenatal or
early postnatal strategies to prevent allergic sensitization.
Studies of animal models have shown that vaccination of
pregnant mice with molecules that induce allergen-speciﬁc
IgG, or administration of allergen-speciﬁc IgG, prevented
allergic sensitization in offspring.134,135 There is evidence
that post-natal administration of hydrolyzed milk that con-
tains allergen-derived peptides can induce tolerance.136
However, a recent study in which children at risk for ce-
liac disease were given gluten as infants showed no ef-
fects.137 Research programs are underway to determine
when and how best to expose infants to potential allergens
(eg, peanut allergens) to avoid sensitization and/or induce
tolerance.138
In addition to prenatal approaches, strategies also might
be developed to prevent allergy based on early vaccination
or administration of allergen-speciﬁc IgG shortly after
birth.139 In addition to subcutaneous administration,
immunotherapy for food allergy can be given by sublingual,
oral, or epitcutaneous delivery.140 Sublingual therapy has
been used for therapeutic vaccination but recently was
found to be safe and induce tolerance in children with IgE
sensitization but without allergic symptoms.141 Clinical
studies of patients with egg or peanut allergies found that
oral immunotherapy not only is effective for treatment,66
but also induces sustained protection, for up to 5 years.142
Various forms of oral immunotherapy currently are used
in different countries.
We need to identify disease-relevant allergens as well as
windows for early intervention if we are to developpreventive allergen-speciﬁc treatments. Studies are underway
in birth cohorts. Because of the higher prevalence of respi-
ratory allergies than food allergies, it is likely that ﬁrst clinical
prevention studies will be performed for respiratory aller-
gens. However, ﬁndings should be applicable to food allergies.
Speciﬁc immunotherapy of sensitized patients with
recombinant and synthetic vaccines is most advanced for
respiratory allergies, but approaches applied to respiratory
allergens will be used to help develop deﬁned vaccines for
food allergy. Hypoallergenic allergen derivatives already
have been made for several important food allergens and
were evaluated in vitro and in animal models143; a vaccine
for ﬁsh allergies has been administered safely to patients in a
clinical trial.133 We therefore can expect profound advances
in sublingual immunotherapy for food allergies through
recombinant allergen-based vaccines in the near future.Supplementary Material
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Supplementary Table 1.Mechanisms and Clinical Manifestations of IgE-Associated Food allergy
Organ system Clinical manifestations Immunopathology Features Age and natural course
Skin Urticaria, angioedema
Flush, pruritus
Oral allergy syndrome (local itching and
tingling and/or edema of lips, tongue,
palate and pharynx)
IgE-mediated mast cell/basophil
degranulation
Acute onset after food ingestion
(minutes-hours)
In infants and adults, may resolve
with age
Appears mainly in adults with
established pollen allergies,
long-lived, boosted by pollen
contact
Contact urticaria After direct skin contact In infants and adults
Atopic dermatitis
Protein contact dermatitis
T cell-mediated (with or without
involvement of IgE)
Delayed type reaction > 24 hours after
food ingestion
In infants and adults
Respiratory tract Laryngeal and/or pharyngeal edema
Hoarseness, cough
IgE-mediated mast cell/basophil
degranulation
Acute onset after food ingestion
(minutes-hours)
In infants and adults
Rhinoconjunctivitis
Bronchial asthma
T cell-mediated (with or without
involvement of IgE)
Delayed type reaction > 24 hours after
food ingestion
In infants and adults
Baker’s asthma in adults
Gastrointestinal
tract
Colitis
Diarrhea
Gastroenteritis
Anorexia
Nausea, vomiting
Abdominal pain
Flatulence
Abdominal distension
IgE-mediated mast cell/basophil
degranulation
Acute onset after food ingestion
(minutes-hours)
In infants and adults
Gastroenteritis T cell-mediated (with or without
involvement of IgE)
Delayed type reaction > 24 hours after
food ingestion, increased pro-
inﬂammatory cytokine responses
In infants and adults, may resolve
with age
Eosinophilic gastroenteritis
Eosinophilic esophagitis
Eosinophilic gastroenteritis Eosinophil-activation by cytokines In infants and adults
Cardiovascular
system
Tachycardia
Hypotension
Vascular collapse
Anaphylactic shock
Cardiac dysrhythmia
IgE-mediated mast cell/basophil
degranulation
Acute onset after food ingestion
(minutes-hours)
In infants and adults
Nervous system Irritability
Anxiety
IgE-mediated mast cell/basophil
degranulation?
Acute onset after food ingestion
(minutes-hours)
In infants and adults
Confusion and/or and/or
Loss of consciousness T cell-mediated (with or without
involvement of IgE)?
Delayed type reaction > 24 hours after
food ingestion
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